Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2 mutated metastatic breast cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 11.06.19
Views: 324

Dr Adrienne Waks - Dana-Farber Cancer Institute, Boston, USA

Dr Adrienne Waks speaks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about the mechanisms of resistance to platinum-based chemotherapy or PARP inhibitors in patients with BRCA1/2 mutated, metastatic breast cancer.

Dr Waks explains the preliminary findings of this study, in which 50 percent of patients acquired resistance as their tumours were no longer a BRCA1/2 mutant.

The protein RAD51 was also investigated as a potential biomarker, to determine the potency of BRCA1/2.

Dr Waks discusses the feasibility of implementing these techniques in the clinic, along with further work that will need to be carried out.

Related videos

follow us

Donate to ecancer

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation